PDF(Pubmed)
Abstract：
UNASSIGNED: Patients who previously underwent surgical resection of initial primary lung cancer are at a high risk of developing multiple primary lung cancers (MPLCs). The purpose of this study was to compare the efficacy and safety between stereotactic body radiation therapy (SBRT) and surgery for MPLCs patients after prior radical resection for the first lung cancers.
UNASSIGNED: In this multicenter retrospective study, eligible MPLC patients with tumor diameter of 5.0 cm or less at N0M0 who underwent SBRT or reoperation between January 2013 and August 2020 were enrolled. The primary endpoint was the 3-year locoregional recurrence and treatment-related toxicity. Kaplan-Meier method was used to calculate survival rates. The χ2 test was adapted to assess the difference of categorical variables between the two subgroup patients.
UNASSIGNED: A total of 203 (73 in the SBRT group and 130 in the surgery group) patients from three academic cancer centers were evaluated with a median follow-up of 38.3 months. The cumulative 1-, 2-, and 3-year incidences of locoregional recurrence were 5.6 %, 7.0 % and 13.1 % in the SBRT group versus 3.2 %, 4.8 % and 7.4 % in the surgery group, respectively [hazard ratio (HR), 1.97; 95 % confidence interval (CI), 0.74-5.24; P = 0.14]. The cancer-specific survival rates were 95.9 %, 94.5 % and 88.1 % versus 96.9 %, 94.6 % and 93.8 % in the SBRT and surgery groups respectively (HR, 1.72; 95 % CI, 0.67-4.44; P = 0.23). In the SBRT group, two patients (2.7 %) suffered from grade 3 radiation pneumonitis, while in the surgery group, grade 3 complications occurred in four (3.1 %) patients, and four cases were expired due to pneumonia or pulmonary heart disease within 90 days after surgery.
UNASSIGNED: SBRT is an effective therapeutic option with limited toxicity compared to surgery for patients with MPLCs after prior radical surgical resection, and it could be considered as an alternative treatment for those patients.
UNASSIGNED: In this multicenter retrospective study, eligible MPLC patients with tumor diameter of 5.0 cm or less at N0M0 who underwent SBRT or reoperation between January 2013 and August 2020 were enrolled. The primary endpoint was the 3-year locoregional recurrence and treatment-related toxicity. Kaplan-Meier method was used to calculate survival rates. The χ2 test was adapted to assess the difference of categorical variables between the two subgroup patients.
UNASSIGNED: A total of 203 (73 in the SBRT group and 130 in the surgery group) patients from three academic cancer centers were evaluated with a median follow-up of 38.3 months. The cumulative 1-, 2-, and 3-year incidences of locoregional recurrence were 5.6 %, 7.0 % and 13.1 % in the SBRT group versus 3.2 %, 4.8 % and 7.4 % in the surgery group, respectively [hazard ratio (HR), 1.97; 95 % confidence interval (CI), 0.74-5.24; P = 0.14]. The cancer-specific survival rates were 95.9 %, 94.5 % and 88.1 % versus 96.9 %, 94.6 % and 93.8 % in the SBRT and surgery groups respectively (HR, 1.72; 95 % CI, 0.67-4.44; P = 0.23). In the SBRT group, two patients (2.7 %) suffered from grade 3 radiation pneumonitis, while in the surgery group, grade 3 complications occurred in four (3.1 %) patients, and four cases were expired due to pneumonia or pulmonary heart disease within 90 days after surgery.
UNASSIGNED: SBRT is an effective therapeutic option with limited toxicity compared to surgery for patients with MPLCs after prior radical surgical resection, and it could be considered as an alternative treatment for those patients.
摘要：
未经证实：先前曾接受手术切除初始原发性肺癌的患者发生多原发性肺癌(MPLCs)的风险很高。这项研究的目的是比较立体定向放射治疗（SBRT）和手术之间的疗效和安全性。
未经评估：在这项多中心回顾性研究中，纳入2013年1月至2020年8月期间接受SBRT或再次手术的N0M0时肿瘤直径小于或等于5.0cm的MPLC患者.主要终点是3年局部复发和治疗相关毒性。采用Kaplan-Meier法计算生存率。χ2检验适用于评估两个亚组患者之间分类变量的差异。
UNASSIGNED：对来自三个学术癌症中心的203名患者（SBRT组73名，手术组130名）进行了评估，中位随访时间为38.3个月。累计1-，2-,局部区域复发的3年发生率为5.6%，SBRT组的7.0%和13.1%，与3.2%相比，手术组分别为4.8%和7.4%,分别为[危险比(HR)，1.97；95%置信区间(CI)，0.74-5.24；P=0.14]。癌症特异性生存率为95.9%，94.5%和88.1%对96.9%，SBRT组和手术组分别为94.6%和93.8%(HR，1.72；95%CI，0.67-4.44；P=0.23）。在SBRT组中，两名患者(2.7%)患有三级放射性肺炎，在手术组，4例(3.1%)患者发生3级并发症,四例在手术后90天内因肺炎或肺心病而过期。
UNASSIGNED：SBRT是一种有效的治疗选择，与先前根治性手术切除后的MPLCs患者相比，其毒性有限，它可以被认为是这些患者的替代疗法。
未经评估：在这项多中心回顾性研究中，纳入2013年1月至2020年8月期间接受SBRT或再次手术的N0M0时肿瘤直径小于或等于5.0cm的MPLC患者.主要终点是3年局部复发和治疗相关毒性。采用Kaplan-Meier法计算生存率。χ2检验适用于评估两个亚组患者之间分类变量的差异。
UNASSIGNED：对来自三个学术癌症中心的203名患者（SBRT组73名，手术组130名）进行了评估，中位随访时间为38.3个月。累计1-，2-,局部区域复发的3年发生率为5.6%，SBRT组的7.0%和13.1%，与3.2%相比，手术组分别为4.8%和7.4%,分别为[危险比(HR)，1.97；95%置信区间(CI)，0.74-5.24；P=0.14]。癌症特异性生存率为95.9%，94.5%和88.1%对96.9%，SBRT组和手术组分别为94.6%和93.8%(HR，1.72；95%CI，0.67-4.44；P=0.23）。在SBRT组中，两名患者(2.7%)患有三级放射性肺炎，在手术组，4例(3.1%)患者发生3级并发症,四例在手术后90天内因肺炎或肺心病而过期。
UNASSIGNED：SBRT是一种有效的治疗选择，与先前根治性手术切除后的MPLCs患者相比，其毒性有限，它可以被认为是这些患者的替代疗法。
